October 2009
Worldwide Biotech;Oct2009, Vol. 21 Issue 10, p8
Trade Publication
The article reports that the mammalian target of rapamycin (mTOR ) inhibitor TORISEL (R) (temsirolimus) has been approved by the European Commission for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL). Torisel is said to be used for the first-line treatment of patients with advanced renal cell carcinoma. It looks at TORISEL as an important option for the allegedly difficult-to-treat disease, relapsed and refractory mantle cell lymphoma.


Related Articles

  • Progression-free survival 'doubles' in renal cell carcinoma. Fricker, Janet // British Journal of Hospital Medicine (17508460);Oct2008, Vol. 69 Issue 10, p555 

    The article provides information on the update of the phase III Record 1 study presented at the European Society for Medical Oncology (ESMO), regarding the therapeutic use of RAD001, a once-daily oral therapy inhibiting the M-TOR or mammalian target of rapamycin protein in treating cancer. It...

  • Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma. Sun, Maxine; Abdollah, Firas; Schmitges, Jan; Jeldres, Claudio; Shariat, Shahrokh F.; Perrotte, Paul; Karakiewicz, Pierre I. // Research & Reports in Urology;2011, Issue 3, p43 

    The efficacy of sequential everolimus, an orally administered inhibitor of mammalian target of rapamycin (mTOR), was proven in a placebo-controlled phase III study, where median progression-free survival was 4.9 vs 1.9 months for placebo (hazard ratio: 0.33, P , 0.001). Placebo crossovers (80%)...

  • YM155 reverses rapamycin resistance in renal cancer by decreasing survivin. Koike, Hidekazu; Nitta, Takashi; Sekine, Yoshitaka; Arai, Seiji; Furuya, Yosuke; Nomura, Masashi; Matsui, Hiroshi; Shibata, Yasuhiro; Ito, Kazuto; Oyama, Tetsunari; Suzuki, Kazuhiro // Journal of Cancer Research & Clinical Oncology;Oct2014, Vol. 140 Issue 10, p1705 

    Purpose: Mammalian target of rapamycin inhibitor has exhibited promising anticancer activity for the treatment of renal cell carcinoma (RCC). However, many patients acquire resistance to therapeutic agents leading to treatment failure. The objective of this study was to determine whether...

  • Targeted Therapies.  // Current Medical Literature: Kidney Cancer;Sep2009, Vol. 1 Issue 3, p74 

    The article focuses on the efficiency of sunitinib and Temsirolimus as treatment for renal cell carcinoma (RCC) pancreatic metastasis in Great Britain. The use of sunitinib as a therapeutic treatment has been viewed efficient after completing one remission (CR), four partial remissions (PR) in...

  • Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Flaig, T. W.; Costa, L. J.; Gustafson, D. L.; Breaker, K.; Schultz, M. K.; Crighton, F.; Kim, F. J.; Drabkin, H. // British Journal of Cancer;9/7/2010, Vol. 103 Issue 6, p796 

    Background: The mammalian target of rapamycin (mTOR) is an important therapeutic target in the treatment of renal cell carcinoma (RCC). Pre-clinical data indicate that the combined inhibition of both the epidermal growth factor receptor and mTOR results in enhanced anticancer...

  • mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma. Bailey, Sean T.; Zhou, Bing; Damrauer, Jeffrey S.; Krishnan, Bhavani; Wilson, Harper L.; Smith, Aleisha M.; Li, Mingqing; Yeh, Jen Jen; Kim, William Y. // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1 

    Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors. We sought to investigate the relative efficacy of allosteric versus...

  • Targeted therapy improved OS in mRCC. Southall, Jennifer; Todak, Alexandra // Hem/Onc Today;1/10/2014, Vol. 15 Issue 1, p13 

    The article discusses the retrospective study by A.V. Soerensen, published in November 8, 2013 issue of "European Journal of Cancer," that found improvement in treatment rates and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) with implementation of targeted therapy.

  • Sirolimus.  // Reactions Weekly;2/20/2010, Issue 1289, p38 

    The article describes the case of a 64-year-old woman who acquired interstitial pneumonitis while undergoing treatment with sirolimus.

  • Mycophenolic acid/sirolimus/tacrolimus.  // Reactions Weekly;3/13/2010, Issue 1292, p26 

    The article describes the case of a 40-year-old woman who developed oral ulcers while undergoing treatment with mycophenolic acid, sirolimus and tacrolimus.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics